EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ciprofloxacin prophylaxis during haematopoietic cell transplantation: a role for use in patients with germ cell tumours?

Konstantinos Kavallieros, Ioannis Baltas, Giannis Konstantinou, Eirini Koutoumanou, Malick M Gibani, Mark Gilchrist, Frances Davies, Jiri Pavlu

Journal of Medical Microbiology · 2024

DOI: 10.1099/jmm.0.001847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2024. Verfasst von Konstantinos Kavallieros und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Ciprofloxacin, Hematopoietic Stem Cell Transplantation, Neoplasms, Germ Cell and Embryonal, Antibiotic Prophylaxis. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Fluoroquinolone prophylaxis during haematopoietic cell transplantation (HCT) can lead to antimicrobial resistance (AMR). Identifying the groups of patients that have the highest likelihood of benefiting from prophylactic antimicrobials is important for antimicrobial stewardship (AMS). Hypothesis. We aimed to identify groups of HCT recipients that have the highest likelihood of benefiting from prophylactic fluroquinolones.

Methods

All admissions for HCT in a tertiary centre between January 2020 and December 2022 ( N = 400) were retrospectively studied. Allogeneic HCT (allo-HCT) recipients had prophylaxis with ciprofloxacin during the chemotherapy-induced neutropenia, while autologous HCT (auto-HCT) recipients did not. Bacteraemias were recorded when non-contaminant bacterial pathogens were isolated in blood cultures.

Results

Allo-HCT was performed for 43.3 % (173/400) of patients and auto-HCT was performed for 56.7 % (227/400). A bacteraemia was documented in 28.3 % (113/400) of cases. Allo-HCT recipients were more likely to have a Gram-positive bacteraemia (20.8%, 36/173, vs 10.1%, 23/227, P = 0.03), while a difference was not observed for Gram-negative bacteraemias (18.5%, 32/173 vs 18.1%, 41/227, P = 0.91). Among auto-HCT recipients not receiving ciprofloxacin prophylaxis, patients with germ cell tumours had the highest probability ( P for trend 0.09) of recording any bacteraemia (43.5%, 10/23) followed by patients with lymphomas (32.5%, 13/40), other auto-HCT indications (22.2%, 2/9), multiple myeloma (22.1%, 29/131) and multiple sclerosis (12.5%, 3/24). The higher number of bacteraemias in patients with germ cell tumours was primarily driven by Gram-negative pathogens.

Conclusions

Ciprofloxacin prophylaxis was associated with a reduced incidence of Gram-negative bacteraemias in allo-HCT recipients. Auto-HCT recipients due to germ cell tumours, not receiving ciprofloxacin prophylaxis, recorded the highest incidence of bacteraemias and represent a possible target group for this intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CiprofloxacinHematopoietic Stem Cell TransplantationNeoplasms, Germ Cell and EmbryonalAntibiotic ProphylaxisAnti-Bacterial AgentsBacteremiaHumansMaleRetrospective StudiesMiddle AgedFemaleAdultAgedYoung AdultNeutropeniaAntimicrobial StewardshipAdolescent

Stichwörter der Autor:innen

allograftsantimicrobial drug resistanceautograftsciprofloxacingerm cell and embryonalhematopoietic stem cell transplantationneoplasms

Substanzen

CiprofloxacinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Imperial College London, London, UK.
  • Department of Infection, Immunity and Inflammation, Institute of Child Health, University College London, London, UK.
  • Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Population, Policy & Practice Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Department of Infectious Disease, Imperial College NHS Healthcare Trust, St Mary's Hospital, London, UK.

Förderung

  • Wellcome Trust

Zitieren

APA

Kavallieros, K., Baltas, I., Konstantinou, G., Koutoumanou, E., Gibani, M. M., Gilchrist, M., Davies, F., & Pavlu, J. (2024). Ciprofloxacin prophylaxis during haematopoietic cell transplantation: a role for use in patients with germ cell tumours?. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001847

Vancouver

Kavallieros K, Baltas I, Konstantinou G, Koutoumanou E, Gibani MM, Gilchrist M, et al. Ciprofloxacin prophylaxis during haematopoietic cell transplantation: a role for use in patients with germ cell tumours?. Journal of Medical Microbiology. 2024. doi:10.1099/jmm.0.001847

BibTeX
@article{Kavallieros2024,
  author = {Kavallieros, Konstantinos and Baltas, Ioannis and Konstantinou, Giannis and Koutoumanou, Eirini and Gibani, Malick M and Gilchrist, Mark and Davies, Frances and Pavlu, Jiri},
  title = {Ciprofloxacin prophylaxis during haematopoietic cell transplantation: a role for use in patients with germ cell tumours?},
  journal = {Journal of Medical Microbiology},
  year = {2024},
  doi = {10.1099/jmm.0.001847}
}
Kostenlos starten →